Urinary tract infections (UTI) are often caused by bacteria and are frequently treated with antibiotics, such as fluoroquinolones. Fluoroquinolones have been recommended empirical therapy for treatment of complicated UTIs. Research indicates that Ciprofloxacin has high activity against E. coli that causes the majority of these infections. This new extended release formulation of ciprofloxacin may provide a convenient once-daily treatment option for these difficult-to treat infections. The once-daily formulation enables the rapid release of ciprofloxacin, which distributes to the serum and tissues within hours. This is followed by a second extended release of the active ingredient, which produces 24-hour urine concentrations.
Research study compared 1000mg once-daily Cipro XR to a twice-daily 500 mg dose of conventional Cipro. Patients were evaluated based on the presence of UTI. Evaluation was based on bacteriologic and clinical outcomes. Bacteriological eradication
was achieved in 89 percent of patients treated with once-daily Cipro XR and 85 percent of patients treated with conventional twice-daily Cipro. Clinical cure was observed in 97 percent of patients treated once a day with Cipro XR 1000mg, compared with 94 percent of patients receiving the traditional Cipro 500mg twice daily. This indicates safety and efficacy profile of once-daily Cipro(R) XR is Comparable to Conventional CIPRO(R) in treating Complicated Urinary Tract Infections.